BMJ Open Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study

Megan M Shuey,¹ Jocelyn S Gandelman,² Cecilia P Chung,² Hui Nian,³ Chang Yu,³ Joshua C Denny,⁴ Nancy J Brown^{1,2}

To cite: Shuey MM, Gandelman JS, Chung CP, *et al.* Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study. *BMJ Open* 2018;**8**:e021640. doi:10.1136/bmjopen-2018-021640

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-021640>).

Received 12 January 2018

Revised 1 May 2018

Accepted 17 May 2018

For numbered affiliations see end of article.

Correspondence to

Dr Megan M Shuey;
megan.m.shuey@vanderbilt.edu

ABSTRACT

Objective To identify patients with hypertension with resistant and controlled blood pressure (BP) using electronic health records (EHRs) in order to elucidate practices in the real-world clinical treatment of hypertension and to enable future genetic studies.

Design Using EHRs, we developed and validated algorithms to identify patients with resistant and controlled hypertension.

Setting An academic medical centre in Nashville, Tennessee.

Population European-American (EA) and African-American (AA) patients with hypertension.

Main outcome measures Demographic characteristics: race, age, gender, body mass index, outpatient BPs and the history of diabetes mellitus, chronic kidney disease stage 3, ischaemic heart disease, transient ischaemic attack, atrial fibrillation and sleep apnoea.

Medication treatment All antihypertensive medication classes prescribed to a patient at the time of classification and ever prescribed following classification.

Results The algorithms had performance metrics exceeding 92%. The prevalence of resistant hypertension in the total hypertensive population was 7.3% in EA and 10.5% in AA. At diagnosis, AA were younger, heavier, more often female and had a higher incidence of type 2 diabetes and higher BPs than EA. AA with resistant hypertension were more likely to be treated with vasodilators, dihydropyridine calcium channel blockers and alpha-2 agonists while EA were more likely to be treated with angiotensin receptor blockers, renin inhibitors and beta blockers. Mineralocorticoid receptor antagonists use was increased in patients treated with more than four antihypertensive medications compared with patients treated with three (12.4% vs 2.6% in EA, $p<0.001$; 12.3% vs 2.8% in AA, $p<0.001$). The number of patients treated with a mineralocorticoid receptor antagonist increased to 37.4% in EA and 41.2% in AA over a mean follow-up period of 7.4 and 8.7 years, respectively.

Conclusions Clinical treatment of resistant hypertension differs in EA and AA patients. These results demonstrate

Strengths and limitations of this study

- A strength of this study was the accuracy of the electronic algorithms for the identification of resistant hypertension.
- The use of stringent definitions to phenotype resistant and controlled hypertension in the electronic health record will permit future genetic studies using large-scale electronic health records with linked genetic data.
- The inclusion of a large number of European ($n=13\,541$) and African ($n=3541$) Americans with resistant hypertension allowed us to compare the treatment of hypertension in these two groups.
- The limitations of the study include the inability to confirm medication compliance or track use of over-the-counter medications that affect blood pressure (BP) response, and the lack of ambulatory BP measures in the electronic medical records reviewed.

the feasibility of identifying resistant hypertension using an EHR.

INTRODUCTION

Patients with resistant hypertension, defined as persistently elevated blood pressure (BP) despite concurrent treatment with three or more different antihypertensive medications including a thiazide diuretic, are at an elevated risk of chronic kidney disease (CKD) and a 47% higher risk of cardiovascular events compared with patients with controlled hypertension.^{1,2} The estimated prevalence of resistant hypertension ranges from 8.4% to 50% of all treated patients with hypertension in clinical trials and epidemiological studies due to varying definitions of resistant hypertension and methods of BP assessment.^{3–11}

A meta-analysis by Achelrod *et al* estimated a prevalence of resistant hypertension of 13.72% in 20 observational studies and 16.32% in 4 randomised control trials.¹² These rates are consistent with a separate meta-analysis of North American and European studies that reported a resistant hypertensive prevalence rate of 14.8% in treated patients with hypertension.⁹ These rates may be inflated because the studies did not assess adequacy of drug treatment or medication non-adherence.

The rates of inadequate drug treatment or medication non-adherence are not known precisely for the population. In a study by Egan *et al*, half of the patients with uncontrolled BP on greater than three antihypertensive medications were prescribed optimal treatment and patients with greater cardiovascular risk were more often prescribed optimal treatment.¹³ Medication non-adherence, in particular, may lead to overestimation of the prevalence of resistant hypertension. Studies assessing medication adherence using blood and urine levels to measure antihypertensive medication intake estimate the rate of non-adherence, including partial and complete non-adherence, to be approximately 50% in resistant patients with hypertension and 25% in patients with hypertension with uncontrolled BP.^{14–16} These conditions may contribute to uncontrolled BP in some but not all patients with resistant hypertension. The molecular mechanisms underlying resistant hypertension in the remaining population remain unknown. Therefore, understanding the genetic underpinning of resistant hypertension versus readily controlled hypertension is of great value.

To date, however, the identification of novel genetic underpinnings of population-wide hypertension has met with limited success. Genome-Wide Association Studies (GWAS) can analyse up to millions of genetic variants from across the human genome in an effort to identify genetic risk factors of disease. GWAS studies of BP and hypertension have identified a number of variants that associate with BP and hypertension.^{17–21} The contribution of these variants to the overall heritability of hypertension, however, has been relatively small.^{22–24} Conversely, studies of Mendelian forms of hypertension have identified novel rare variants with large effect size that contribute to hypertension.^{22–25–28} These findings have provided mechanistic insight into the aetiology of hypertension. Resequencing efforts in the Framingham Heart Study have further supported the role for some of these rare variants in BP regulation.²⁹ Because much is still left to learn about the genetic contributions to hypertension, there is a need to study more severe hypertension in large datasets for which clinical and medication data are available. Electronic health records (EHRs) linked with genetic material provides a robust resource to do just that.^{30–31}

We hypothesised that we could use the EHR to develop algorithms to identify patients within a clinical population who had resistant hypertension or controlled hypertension for use in future genetic studies. Resistant hypertensive cases were defined as patients with BP $\geq 140/90$ mm Hg

despite concurrent use of three or more antihypertensive medications including a thiazide, thiazide-like diuretic or a dihydropyridine calcium channel blocker (DHP CCB) or those taking four or more antihypertensive medications including a thiazide, thiazide-like diuretic or DHP CCB. Controls with controlled hypertension were defined as patients with BP $\leq 135/90$ mm Hg on one and only ever one medication. Our case and control definitions were designed to be stringent, excluding secondary causes of hypertension and CKD stages 4 and 5, to select a more homogeneous population for use in genetic studies. The accuracy of the algorithms was validated by chart review. In developing the method, we observed differences in the patterns of prescribing of antihypertensive medications between African-American (AA) and European-American (EA) patients with resistant hypertension. We describe here the characteristics and medication treatment of AA versus EA patients with resistant hypertension at a large academic health centre.

METHODS

Electronic health record

We used the Vanderbilt University Medical Center (VUMC) Synthetic Derivative (SD) for this research. The SD is a de-identified copy of the VUMC EHR system with Health Insurance Portability and Accountability Act identifiers removed by established de-identification software as well as custom algorithms.³² The institutional review board reviewed this project and deemed it exempt as non-human subjects research in accordance with 45 code of federal regulations (CFR) 46. To date the SD contains approximately 2.5 million records and approximately one million of these records contain detailed longitudinal data. The SD contains almost all available clinical data including basic demographics, such as race and sex, text from clinical care notes, laboratory values, inpatient and outpatient medication data, International Classification of Disease (ICD) and Current Procedural Terminology (CPT) codes, and other diagnostic reports.

Resistant hypertension algorithm development

To identify patients with resistant hypertension (cases) and patients with controlled hypertension (controls) in the VUMC SD, we developed the following algorithms, updated and modified from a previously published algorithm to define resistant hypertension within the Electronic Medical Records and Genomics network.^{21–33}

Resistant hypertension was defined by one of two possible case definitions. Case type I identified patients with elevated BP despite simultaneous treatment with at least three different classes of antihypertensive medications, including a thiazide diuretic, amlodipine or other DHP CCB (figure 1). Because thiazide-induced hyponatraemia is a relatively common clinical condition and clinical guidelines suggest thiazide or CCB use, we allowed for the replacement of thiazide diuretics with DHP CCBs.^{34–37} Antihypertensive medication classes were ACE inhibitors,

Figure 1 Diagram of the algorithms for the identification of patients with resistant (cases) and controlled (control) hypertension in Vanderbilt University Medical Center's Synthetic Derivative of the electronic health record. BPs, blood pressures; DBP, diastolic blood pressure; HTN, hypertension; ICD-9, International Classification of Disease, Ninth Revision; SBP, systolic blood pressure.

angiotensin receptor blockers (ARBs), beta blockers (BBs), alpha-2 agonists, CCBs, thiazide and thiazide-like diuretics, aldosterone antagonists, other non-thiazide diuretics, direct-acting vasodilators, alpha antagonists, renin inhibitors and miscellaneous antihypertensives (online supplementary table 1). In the case of combination therapies, each component antihypertensive medication was counted separately. Simultaneous treatment with three different classes of antihypertensive medication was confirmed by documentation in the EHR on two occasions separated by more than 1 month. Uncontrolled hypertension was defined by at least two recorded outpatient measurements of systolic BP (SBP) greater than 140 mm Hg or diastolic BP (DBP) greater than 90 mm Hg at least 1 month after medication criteria were met, as well as by a mean outpatient SBP or DBP calculated as greater than 140/90 mm Hg during the 6 months after the medication criteria were met.

The case type II definition of resistant hypertension identified patients who were treated simultaneously with

four or more classes of antihypertensive medication, including a thiazide-type diuretic, amlodipine or other DHP CCB, as documented on at least two occasions more than 1 month apart, regardless of BP. Patients who met the criteria for case type I but subsequently met the definition of case type II by virtue of having a new medication class added were considered to meet the definition of case type II resistant hypertension for all analyses.

Controls, patients with controlled hypertension, were defined as patients who had been assigned an ICD-9 or ICD-10 code for hypertension (401.* and I10, respectively) and who were treated with a single antihypertensive medication. The control definition required that at least one BP be recorded in the month following the initiation of the antihypertensive medication and that all recorded SBP and DBP in the month were less than 135 and 90 mm Hg, respectively. In addition, these patients never received concurrent treatment with more than one antihypertensive class at any time in the EHR. Therefore, control patients could never be classified as a case

at a different time in the EHR. Because we excluded the majority of treated patients with hypertension, for example, patients who achieve control on two or three antihypertensive medications, our controls do not reflect all patients with controlled hypertension; however, we choose a stringent control definition to facilitate future genetic studies using the identified population.

For all three algorithms, drug exposure to antihypertensive medications was identified in the VUMC SD by electronic-prescribing tools and by using MedEx,³⁸ a natural-language processing tool that recognises medication names and information including drug dose, route, frequency and duration from unstructured clinical documents. We required the presence of at least one of the following identifiers—drug dose, route, frequency or duration—for a MedEx-identified drug to be counted. The utility of these tools for extracting medication data from the EHR has been shown previously.^{39 40}

All patient characteristics—age, gender, body mass index (BMI), BPs and history of type two diabetes mellitus (T2DM), sleep apnoea, ischaemic heart disease (IHD), transient ischaemic attack (TIA), congestive heart failure, atrial fibrillation/flutter and CKD stage 3—were extracted from the VUMC SD using a combination of ICD-9 and ICD-10 codes, CPT codes, laboratory measures, and natural-language processing. For each patient, age and BMI at the earliest time point for which a patient met case or control inclusion criteria, that is the decision date, is reported. All outpatient SBP and DBP collected during the 6 months following the decision date were obtained for each patient and individual means were calculated. History of CKD stage 3 was determined by an estimated glomerular filtration rate $>30\text{ mL/min/1.73 m}^2$ and $<60\text{ mL/min/1.73 m}^2$ calculated using the Modification of Diet in Renal Disease formula⁴¹ at any point before case/control identification or within 6 months of identification. Patient race was administratively assigned in the SD based on either patient or physician report. Previous work has shown that self-identified race is highly correlated with genetic ancestry^{42 43} and administratively assigned race in the VUMC SD is sufficient for many genetic association analyses⁴⁴ and correlates tightly with genetic ancestry.⁴³

Online supplementary table 2 lists exclusion criteria for both cases and controls. Exclusion criteria included recorded ICD-9 and ICD-10 codes for conditions known to cause secondary hypertension. For both case types as well as controls, patients were also excluded if they had left ventricular dysfunction defined as an ejection fraction $\leq 35\%$. Patients with CKD stages 4 and 5, defined by an estimated glomerular filtration rate $<30\text{ mL/min/1.73 m}^2$, were also excluded.

After the algorithms were iteratively refined, a blinded review of randomly chosen, never overlapping, individual electronic medical records were performed to determine electronic algorithm efficacy. Based on a population size of 24 906, all cases and controls regardless of race, review of 138 records would allow us to estimate a

misclassification rate of 10% with a margin of error of 5%. We, therefore, chose to review 150 records to determine algorithm efficacy. Two of three reviewers were not affiliated with the development of the electronic algorithms. Each review drew patient records from the SD that had not been previously reviewed. The algorithms were refined until a negative predictive value (NPV), positive predictive value (PPV), sensitivity and specificity greater than 90% was achieved based on the review of 150 records subdivided equally among the two case types and controls (50 each). The final version of the algorithm is available at Phenotype KnowledgeBase.⁴⁵

Statistical methods

Data are presented as frequencies for categorical variables and median and IQR for continuous variables. Between-group comparisons were made using Pearson test for categorical variables and the Wilcoxon test for continuous variables. The false discovery rate-adjusted p values are reported for the multiple comparisons in medication use. Analyses were conducted for the total group and also within EA or AA. Multivariable logistic regression models for medication use in resistant hypertensive cases were fit for race, age, gender and history of T2DM, sleep apnoea, IHD, TIA, atrial fibrillation/flutter, congestive heart failure with preserved ejection fraction (HFpEF) and CKD stage 3. All statistical analyses were run using the SPSS software V.24 (SPSS) or R V.3.3.0.⁴⁶

Patient and public involvement

Because this study involved the use of a de-identified SD of the EHR, patients were not recruited and there was no intervention. Patients were not specifically involved in the development of the research question or design of the study; however, there has been extensive patient and community engagement in the establishment of the Vanderbilt biobank that includes the SD. A community advisory board within the Vanderbilt Institute for Clinical and Translational Research reviews programmes including the SD. Results of the study will be disseminated to patients through local reporting of the publication.

RESULTS

Algorithm validation

NPV, PPV, sensitivity and specificity of the algorithms for resistant hypertension (case type I and type II) and controlled hypertension (control) were determined after a blinded chart review of 150 patients. The algorithm for case type II had the highest PPV and specificity at 96% and 98%, respectively (table 1). The NPV and sensitivity were each 100% for case type I and control.

Identification of patients with resistant hypertension and controlled hypertension

Using the occurrence of an ICD-9 or ICD-10 code for hypertension, as well as the presence of a SBP or DBP greater than 140 or 90 mm Hg prior to or at ICD-9 or

Table 1 Algorithm validation metrics following blinded chart review

	Resistant hypertension		
	Case type I	Case type II	Control
Positive predictive value	94 (83 to 98)	96 (85 to 99)	92 (80 to 97)
Negative predictive value	100 (95 to 100)	99 (94 to 100)	100 (95 to 100)
Specificity	97 (91 to 99)	98 (92 to 100)	96 (90 to 99)
Sensitivity	100 (91 to 100)	98 (88 to 100)	100 (90 to 100)

Data are presented as % (95% CI).

ICD-10 occurrence, we estimated the total number of patients with hypertension in the VUMC SD to be 247 420 (22.2% of the adult patients in the SD with an available BP measurement), of whom 186 015 were EA (75.2%) and 33 576 were AA (13.6%). A total of 5024 potential EA cases and 2139 potential AA cases were excluded for secondary causes of hypertension. After excluding secondary causes of hypertension, 16.5% of the remaining potential AA cases (n=806) and 11.4% of the potential EA cases (n=1993) were excluded by the algorithm due to the presence of CKD stages 4 and 5. An additional 10 AA cases and 21 EA cases were excluded because of a left ventricular ejection fraction (LVEF) <35% within a year of meeting medication criteria. In total, in the SD after algorithm execution we identified 13 541 EA patients who met one or both of the case definitions for resistant hypertension and 6933 who met the definition for controlled hypertension. We likewise identified 3541 AA cases and 891 AA controls ([figure 1](#)). Based on these estimates, we determined the prevalence of resistant hypertension among patients without CKD stages 4 and 5 in the VUMC SD to be 7.3% for EAs and 10.5% for AAs.

Demographics of the algorithm-identified cases and controls

Regardless of race, patients with resistant hypertension were significantly older, heavier and more likely to have T2DM, sleep apnoea, atrial fibrillation, a history of TIA, IHD or CKD stage 3 compared with controls ([table 2](#)). There were significantly more female controls than cases among EAs, but not among AAs.

Compared with EAs, AA cases and controls were significantly younger, heavier, predominately female and had higher prevalence of T2DM at diagnosis ([table 2](#)). The prevalences of atrial fibrillation, IHD and CKD stage 3 were higher in EA compared with AA cases and controls. The prevalence of HFpEF was significantly higher in AA cases compared with EA cases. The prevalences of sleep apnoea and history of TIA were not significantly different between AA and EA patients.

BP and medication use in patients with resistant hypertension and controlled hypertensive controls

By definition, SBP and DBP were significantly higher in patients with resistant hypertension compared with those with controlled hypertension ([table 2](#)). Also by definition, all patients with resistant hypertension were prescribed either a thiazide type diuretic or a CCB (amlodipine or

other DHP CCB) ([table 3](#)). Patients with resistant hypertension were significantly more likely to be prescribed every class of antihypertensive compared with controls except for miscellaneous antihypertensives.

SBP and DBP were significantly higher in AA compared with EA whether within the resistant hypertensive group or within the controlled hypertensive group ([table 2](#)). Among patients with resistant hypertension, AA were more likely to be prescribed the non-thiazide diuretics, CCBs, alpha-2 agonists, ACE inhibitors and direct-acting vasodilators (minoxidil and hydralazine specifically) than EA patients and less likely to be prescribed ARBs, BBs, torsemide or renin inhibitors ([table 3](#)). In multivariable logistic regression models including age, race, gender and history of T2DM, sleep apnoea, atrial fibrillation, TIA, IHD, HFpEF and CKD stage 3, race remained a significant independent predictor of torsemide (p=0.002), ARB (p<0.001), BB (p<0.001), CCB (p<0.001), DHP CCB (p<0.001), alpha-2 agonist (p<0.001), direct-acting vasodilator (p<0.001), minoxidil (p<0.001), hydralazine (p<0.001) and renin inhibitor (p<0.001) use.

To better understand prescribing patterns and patient characteristics, we compared patients with resistant hypertension defined by case definition case type I (uncontrolled hypertension despite treatment with three classes of antihypertensive medications) versus those defined by case type II (patients with hypertension prescribed four or more classes of antihypertensive medications). Patients defined by case type II were heavier, more often male and more likely to have T2DM, IHD, CKD stage 3, HFpEF and sleep apnoea than those defined by the case type I definition (online supplementary table 3). Among EA, case type II patients were more likely to have atrial fibrillation than case type I patients (online supplementary table 3). Among AA, case type II patients were significantly older than case type I patients (online supplementary table 3). DBP and SBP were significantly higher in case type I patients than case type II patients (online supplementary table 3) in both racial groups.

Consistent with the case type I algorithm, all patients were prescribed three simultaneous antihypertensive medication classes. All classes of medications were prescribed more frequently in patients who met the case type II definition versus the case type I definition except for thiazide diuretics and ethacrynic acid (in both EA and AA), and miscellaneous antihypertensives, amlodipine

Table 2 Characteristics of EA and AA patients with resistant hypertension (cases) or controlled hypertension (controls)

Variable	EA			AA			EA versus AA		
	Cases (n=13541)	Controls (n=6933)	P values	Cases (n=3541)	Controls (n=891)	P values	Cases P values	Controls P values	
SBP, mm Hg	145.0 (140.0–153.0)	120.8 (114.0–127.0)	<0.001	147.4 (141.0–156.0)	122.0 (115.0–128.0)	<0.001	<0.001	0.001	
DBP, mm Hg	78.0 (70.0–86.0)	74.0 (68.0–80.0)	<0.001	85.0 (76.4–92.2)	75.5 (70.0–81.0)	<0.001	<0.001	<0.001	
Age, years	66.0 (57.0–73.0)	53.0 (43.0–64.0)	<0.001	56.0 (47.0–65.0)	46.0 (34.0–55.0)	<0.001	<0.001	<0.001	
BMI, kg/m ²	30.8 (26.7–35.8)	29.3 (25.4–34.2)	<0.001	32.9 (28.3–38.9)	31.0 (26.3–37.0)	<0.001	<0.001	<0.001	
Female, n (%)	6615 (48.9%)	3495 (50.4%)	0.04	2092 (59.1%)	527 (59.2%)	0.97	<0.001	<0.001	
T2DM, n (%)	2694 (19.9%)	1026 (14.8%)	<0.001	954 (26.9%)	171 (19.2%)	<0.001	<0.001	<0.001	
Sleep apnoea, n (%)	868 (6.4%)	373 (5.4%)	0.003	252 (7.1%)	45 (5.1%)	0.03	0.13	0.68	
Afib, n (%)	1424 (10.5%)	272 (3.9%)	<0.001	130 (3.7%)	11 (1.2%)	<0.001	<0.001	<0.001	
TIA, n (%)	603 (4.5%)	110 (1.6%)	<0.001	176 (5.0%)	19 (2.1%)	<0.001	0.19	0.23	
IHD, n (%)	2493 (18.4%)	585 (8.4%)	<0.001	468 (13.2%)	32 (3.6%)	<0.001	<0.001	<0.001	
CKD 3, n (%)*	4407 (42.4%)	650 (14.1%)	<0.001	870 (29.7%)	47 (7.2%)	<0.001	<0.001	<0.001	
HFpEF, n (%)	1173 (9%)	102 (1%)	<0.001	376 (11%)	16 (2%)	<0.001	<0.001	0.454	

The number of subjects with available eGFR data is: 10 405 EA cases, 4602 EA controls, 2927 AA cases, and 653 AA controls.

Data are presented as median (IQR) unless otherwise indicated.

^{*}The percentage for CKD 3 is based on the number of subjects with available eGFR data, not all subjects in the population.

AA, African-American; Afib, atrial fibrillation; BMI, body mass index; CKD 3, chronic kidney disease stage 3; DBP, diastolic blood pressure; EA, European-American; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; IHD, ischaemic heart disease; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; TIA, transient ischaemic attack.

Table 3 Medication use in EA and AA patients with resistant hypertension (cases) and controlled hypertension (controls)

Variable	EA			AA			EA versus AA	
	Case (n=13541)	Control (n=6933)	P values	Case (n=3541)	Control (n=891)	P values	Case P values	Control P values
Thiazide/CCB, n (%)	13541 (100%)	1167 (16.8%)	<0.001	3541 (100%)	292 (32.8%)	<0.001	1.0	<0.001
ACE inhibitor, n (%)	6999 (51.7%)	2439 (35.2%)	<0.001	1916 (54.1%)	264 (29.6%)	<0.001	0.02	0.003
ARB, n (%)	5178 (38.2%)	728 (10.5%)	<0.001	1161 (32.8%)	54 (6.1%)	<0.001	<0.001	<0.001
BB, n (%)	8697 (64.2%)	1803 (26.0%)	<0.001	1996 (56.4%)	152 (17.1%)	<0.001	<0.001	<0.001
Alpha-2 agonist, n (%)	1921 (14.2%)	140 (2.0%)	<0.001	736 (20.8%)	29 (3.3%)	<0.001	<0.001	0.04
CCB, n (%)	9272 (68.5%)	615 (8.9%)	<0.001	2625 (74.1%)	144 (16.2%)	<0.001	<0.001	<0.001
Amlodipine, n (%)	6759 (49.9%)	318 (4.6%)	<0.001	1749 (49.4%)	90 (10.1%)	<0.001	0.74	<0.001
DHP CCB, n (%)	1508 (11.1%)	75 (1.1%)	<0.001	585 (16.5%)	27 (3.0%)	<0.001	<0.001	<0.001
Non-DHP CCB, n (%)	1005 (7.4%)	222 (3.2%)	<0.001	291 (8.2%)	27 (3.0%)	<0.001	0.18	0.84
Thiazide Diuretic, n (%)	8812 (65.1%)	774 (11.2%)	<0.001	2319 (65.5%)	175 (19.6%)	<0.001	0.76	<0.001
Aldosterone antagonist, n (%)	854 (6.3%)	57 (0.8%)	<0.001	240 (6.8%)	8 (0.9%)	<0.001	0.43	0.85
Non-thiazide Diuretic, n (%)	4271 (31.5%)	326 (4.7%)	<0.001	1190 (33.6%)	56 (6.3%)	<0.001	0.04	0.08
Furosemide, n (%)	3114 (23.0%)	254 (3.7%)	<0.001	874 (24.7%)	44 (4.9%)	<0.001	0.07	0.10
Triamterene, n (%)	1155 (8.5%)	45 (0.7%)	<0.001	352 (9.9%)	11 (1.2%)	<0.001	0.02	0.09
Torsemide, n (%)	176 (1.3%)	17 (0.2%)	<0.001	23 (0.7%)	1 (0.1%)	0.06	0.004	0.57
Bumetanide, n (%)	141 (1.0%)	8 (0.1%)	<0.001	28 (0.8%)	0 (0.0%)	0.01	0.28	0.43
Amiloride, n (%)	32 (0.2%)	1 (0.0%)	<0.001	10 (0.3%)	0 (0.0%)	0.12	0.75	0.79
Ethacrynic acid, n (%)	11 (0.1%)	1 (0.0%)	0.07	7 (0.2%)	0 (0.0%)	0.19	0.10	0.79
Vasodilator, n (%)	903 (6.7%)	17 (0.3%)	<0.001	422 (11.9%)	2 (0.2%)	<0.001	<0.001	0.93
Minoxidil, n (%)	161 (1.2%)	2 (0.0%)	<0.001	101 (2.9%)	0 (0.0%)	<0.001	<0.001	0.75
Hydralazine, n (%)	742 (5.5%)	15 (0.2%)	<0.001	321 (9.1%)	2 (0.2%)	<0.001	<0.001	0.96
Alpha antagonist, n (%)	626 (4.6%)	33 (0.5%)	<0.001	139 (3.9%)	7 (0.8%)	<0.001	0.12	0.33
Renin inhibitor, n (%)	275 (2.0%)	1 (0.0%)	<0.001	43 (1.2%)	0 (0.0%)	0.001	0.004	0.79
Misc antihtn, n (%)	3 (0.0%)	0 (0.0%)	0.21	0 (0.0%)	0 (0.0%)	1.0	0.51	1.0

P values were adjusted to control for false discovery rate.

AA, African-American; ARB, angiotensin II receptor blocker; BB, beta blocker; CCB, calcium channel blocker; DHP, dihydropyridine; EA, European-American; Misc antihtn, miscellaneous antihypertensive.

and amiloride (in AA). In particular, spironolactone use was increased from 2.6% to 12.4% in EA and 2.8% to 12.3% in AA. Among AA, direct-acting vasodilator use was increased from 4.7% to 22.0%, and among EA from 2.8% to 13.0% (table 4).

Among EA case type II patients, 3385 patients (66.1%) were prescribed four different classes of antihypertensive medications, 1373 (26.8%) were prescribed five and 366 (7.1%) were prescribed six. Among AA case type II patients, 935 patients (63.1%) were prescribed four different classes, 416 (28.1%) were prescribed five and 131 (8.8%) were prescribed six different classes of antihypertensive medications.

Online supplementary table 4 lists the number of case type II patients prescribed specific medication classes at initial diagnosis and at any point following their identification. There was an increase in prescription rate for all classes when the time frame was extended to include any point in the SD following initial identification of resistant hypertension. 37.4% of EA and 41.2% of AA case type II patients were eventually prescribed an

aldosterone antagonist. While less than half (46.6%) of EA case type II patients were ever prescribed an alpha-2 agonists such as clonidine, more than half (56.4%) of AA case type II patients were ever prescribed an alpha-2 agonist.

DISCUSSION

We developed algorithms to identify patients with resistant hypertension and with controlled hypertension using the EHR. Electronic support has been shown to improve accuracy of clinical data acquisition and to improve control of major cardiovascular risk factors.⁴⁷ The algorithms exhibited high accuracy with PPVs, NPVs, sensitivity and specificity measures all exceeding 92%. We found that the characteristics of patients with resistant hypertension identified through EHR were similar to those reported previously in observational studies. We identified significant differences in the pharmacological treatment of resistant hypertension in patients of European and African ancestry.

Table 4 Medication use in EA and AA patients with resistant hypertension based on case type definition

Variable	EA			AA			EA versus AA	
	Case I (n=8417)	Case II (n=5124)	P values	Case I (n=2059)	Case II (n=1482)	P values	Case I P values	Case II P values
Thiazide/CCB, n (%)	8417 (100%)	5124 (100%)	1.0	2059 (100%)	1482 (100%)	1.0	1.0	1.0
ACE inhibitor, n (%)	4051 (48.1%)	2948 (57.5%)	<0.001	1037 (50.4%)	879 (59.3%)	<0.001	0.14	0.32
ARB, n (%)	2861 (34.0%)	2317 (45.2%)	<0.001	571 (27.7%)	590 (39.8%)	<0.001	<0.001	<0.001
BB, n (%)	4718 (56.1%)	3979 (77.7%)	<0.001	934 (45.4%)	1062 (71.7%)	<0.001	<0.001	<0.001
Alpha-2 agonist, n (%)	544 (6.5%)	1377 (26.9%)	<0.001	237 (11.5%)	499 (33.7%)	<0.001	<0.001	<0.001
CCB, n (%)	5297 (62.9%)	3975 (77.6%)	<0.001	1433 (69.6%)	1192 (80.4%)	<0.001	<0.001	0.05
Amlodipine, n (%)	4027 (47.8%)	2732 (53.3%)	<0.001	1000 (48.6%)	749 (50.5%)	0.26	0.64	0.13
DHP CCB, n (%)	752 (8.9%)	756 (14.8%)	<0.001	293 (14.2%)	292 (19.7%)	<0.001	<0.001	<0.001
Non-DHP CCB, n (%)	518 (6.2%)	487 (9.5%)	<0.001	140 (6.8%)	151 (10.2%)	<0.001	0.39	0.52
Thiazide diuretic, n (%)	5448 (64.7%)	3364 (65.7%)	0.28	1363 (66.2%)	956 (64.5%)	0.30	0.31	0.52
Aldosterone antagonist, n (%)	219 (2.6%)	635 (12.4%)	<0.001	58 (2.8%)	182 (12.3%)	<0.001	0.64	0.91
Non-thiazide Diuretic, n (%)	1643 (19.5%)	2628 (51.3%)	<0.001	397 (19.3%)	793 (53.5%)	<0.001	0.84	0.24
Furosemide, n (%)	1074 (12.8%)	2040 (39.8%)	<0.001	241 (11.7%)	633 (42.7%)	<0.001	0.31	0.11
Triamterene, n (%)	599 (7.1%)	556 (10.9%)	<0.001	171 (8.3%)	181 (12.2%)	<0.001	0.13	0.25
Torsemide, n (%)	43 (0.5%)	133 (2.6%)	<0.001	4 (0.2%)	19 (1.3%)	<0.001	0.12	0.01
Bumetanide, n (%)	47 (0.6%)	94 (1.8%)	<0.001	8 (0.4%)	20 (1.3%)	0.002	0.46	0.31
Amiloride, n (%)	5 (0.1%)	27 (0.5%)	<0.001	3 (0.1%)	7 (0.5%)	0.08	0.31	0.84
Ethacrynic acid, n (%)	4 (0.0%)	7 (0.1%)	0.09	2 (0.1%)	5 (0.3%)	0.12	0.51	0.21
Vasodilator, n (%)	236 (2.8%)	667 (13.0%)	<0.001	96 (4.7%)	326 (22.0%)	<0.001	<0.001	<0.001
Minoxidil, n (%)	27 (0.3%)	134 (2.6%)	<0.001	7 (0.3%)	94 (6.3%)	<0.001	0.91	<0.001
Hydralazine, n (%)	209 (2.5%)	533 (10.4%)	<0.001	89 (4.3%)	232 (15.7%)	<0.001	<0.001	<0.001
Alpha antagonist, n (%)	159 (1.9%)	467 (9.1%)	<0.001	35 (1.7%)	104 (7.0%)	<0.001	0.64	0.03
Renin inhibitor, n (%)	58 (0.7%)	217 (4.2%)	<0.001	11 (0.5%)	32 (2.2%)	<0.001	0.52	<0.001
Misc antihypertensive, n (%)	0 (0.0%)	3 (0.1%)	0.03	0 (0.0%)	0 (0.0%)	1.0	1.0	0.47

P values were adjusted to control for false discovery rate.

AA, African-American; ARB, angiotensin receptor blocker; BB, beta blocker; CCB, calcium channel blocker; DHP, dihydropyridine; EA, European-American; Misc antihypertensive, miscellaneous antihypertensive.

We observed a prevalence of resistant hypertension of 7.3% in EA and 10.6% in AA, at the lower end of prevalence estimates of 8.4%–50% from previous epidemiological studies and clinical trials.^{3–11} The exclusion of patients with CKD stages 4 and 5,^{48–50} as well as of patients with secondary causes of hypertension likely accounts for the lower prevalence rates. Consistent with prior studies, the prevalence of resistant hypertension was greater among AA compared with EA, and patients with resistant hypertension were significantly older, heavier, more likely to have CKD stage 3, and had a higher incidence of T2DM than patients with controlled hypertension.^{1, 48–51} While the prevalence of sleep apnoea was higher in patients with resistant hypertension compared with patients with controlled hypertension, the prevalence among resistant hypertensive patients in the current study, in which sleep apnoea was diagnosed by ICD-9 or ICD-10 code, is lower than that reported in previous studies in which sleep apnoea was defined prospectively,^{52–54} suggesting the need for more rigorous diagnostic approaches to sleep apnoea in the clinical setting. The prevalence of CKD

stage 3 was increased in EA compared with AA among both cases and controls. This unexpected finding likely resulted from the exclusion of glomerulonephritis, as a secondary cause of hypertension.^{55, 56} In addition, a higher proportion of AA with resistant hypertension was excluded for CKD stages 4 and 5 compared with EA.^{55, 57, 58}

Importantly, we found that prescribing trends differed in EA and AA patients with resistant hypertension. AA patients were more likely to be treated with direct-acting vasodilators, hydralazine and minoxidil and less likely to receive an ARB or renin inhibitor compared with EA. The prevalence of salt-sensitive hypertension is increased in AA compared with EA patients with hypertension, and thiazide-type diuretics and vasodilators are most effective in salt-sensitive hypertension.^{59–61} Hydralazine has also been shown to reduce mortality in AA treated for heart failure⁶² and awareness of this may account for increased use.^{63, 64} The lower use of ARBs and renin inhibitors in AA may reflect clinician awareness of reduced efficacy of drugs that interrupt the renin–angiotensin–aldosterone system (RAAS) in studies of AA.^{65–67} Thiazide diuretics

or DHP CCBs, used by definition in all patients classified as having resistant hypertension, enhance the response to RAAS interrupting drugs in AA, however.⁶⁸ Similarly aliskiren may decrease BP in patients with resistant hypertension who do not respond to spironolactone.⁶⁹ For these reasons, the decreased use of ARBs and renin inhibitors in AA with resistant hypertension prescribed a thiazide diuretic or DHP CCB is surprising. Whether differences in patterns of drug treatment in AA and EA patients with resistant hypertension reflect personalised prescribing or prescribing bias requires further study.

We also evaluated trends in the escalation of antihypertensive treatment in resistant hypertension by comparing medication use between case types I and II. The efficacy of spironolactone as an add-on therapy for BP lowering in patients with resistant hypertension has been supported by many studies and is suggested as a fourth-line treatment by various international guidelines.^{37 70–75} In the present clinical population aldosterone antagonist use increased with the addition of a fourth med with a prescription rate of approximately 3% in case type I patients compared with 12% in case type II patients, regardless of race. With extended follow-up of patients who met the case type II definition, use of an aldosterone antagonist increased to 37.4% in EA and to 41.2% in AA.

The identification of the resistant hypertensive population using the EHR is not without limitations. First, patients may not adhere to prescribed medication. The true prevalence of medication non-adherence in the resistant hypertensive population is unknown and the estimates from various studies range from as low as 16% up to 53%.^{15 76–78} While we could confirm that patients with resistant hypertension were prescribed three or more antihypertensive medication classes simultaneously in their EHR, without directly measuring the medication or its metabolites in a patient's plasma or urine we are unable to confirm adherence. Using a pharmacy fill rate of <80% to exclude patients who were non-adherent with antihypertensive medications, Pimienta and Calhoun reported an incidence of true resistant hypertension of 1.9%.⁷⁹ We recently reported a rigorous adherence rate of 58.8%, among hypertensive patients in an emergency department prescribed three or more antihypertensive medications based on the detection of drugs in the plasma.¹⁴ Second, we used outpatient office BP measurements to define resistant hypertension in the EHR, but ambulatory measurements would be necessary to distinguish between apparent resistant and true resistant hypertension.⁷ Lastly, it is possible that offsite prescriptions or discontinuations of antihypertensive medications were not captured in the EHR; we overcame this potential limitation by requiring repeated documentation of a medication over more than a month in the study algorithms. Nevertheless, in summary, we demonstrate the feasibility of identifying a large number of patients with resistant hypertension and controlled hypertension using an EHR. Using the methodology, we replicated findings previously reported in population studies,^{1 9 80} and identified differing patterns

of antihypertensive medication use in AA and EA with resistant hypertension. Because our data are from a real-world clinical population, the findings are more generalisable to other clinical populations. Future research using these algorithms has the potential to provide larger patient populations than have been studied previously for the evaluation of outcome studies as well as genetic associations in any system where the EHRs are linked to DNA.

Author affiliations

¹Department of Pharmacology, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

²Department of Medicine, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

³Department of Biostatistics, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

⁴Department of Biomedical Informatics, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

Acknowledgements The authors would like to thank Dan Roden and James (Matt) Luther for their clinical suggestions that were instrumental in refining the resistant hypertension and controlled hypertension algorithms.

Contributors MMS, JCD and NJB contributed to the design of the study. MMS, JSG, CPC, HN, CY and NJB contributed to the analysis and interpretation of the results. MMS and NJB contributed to the drafting of the manuscript. MMS, JSG, CPC, HN, CY, JCD and NJB contributed to the editing of the manuscript and final approval for submission. Dan Roden and Matt Luther contributed clinical insight that was instrumental to the creation of the algorithms; their contributions are outlined in the acknowledgements.

Funding This study was supported by the National Institutes of Health (DK108444, K23AR064768, U01HG008672, HL125426 and DK038226) and a Rheumatology Research Foundation K-supplement. The datasets used for the analyses described were obtained from Vanderbilt University Medical Center's Synthetic Derivative, which is supported by institutional funding, the 1S10RR025141 instrumentation award and by the CTSA grant UL1TR000445 from National Center for Advancing Translational Sciences/National Institutes of Health.

Disclaimer MMS affirms that the manuscript is an honest, accurate and transparent account of the study being reported; that no important aspects of the study have been omitted and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Competing interests NJB reports consulting for Shire HGT, Novartis Pharmaceuticals, Viamet Pharmaceuticals and serving on the Advisory Board of Alnylam Pharmaceuticals.

Patient consent Not required.

Ethics approval The study was approved by the Vanderbilt University Medical Center Institutional Review Board (#130848).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The full dataset is available on request to the corresponding author.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Calhoun DA, Jones D, Textor S, *et al.* Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee

- of the Council for High Blood Pressure Research. *Hypertension* 2008;51:1403–19.
2. Daugherty SL, Powers JD, Magid DJ, *et al.* Incidence and prognosis of resistant hypertension in hypertensive patients. *Circulation* 2012;125:1635–42.
 3. Jamerson K, Weber MA, Bakris GL, *et al.* Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med* 2008;359:2417–28.
 4. Hans S, Reilly JP. Resistant hypertension in 2017. *Curr Opin Cardiol* 2017;32:389–96.
 5. Cai A, Calhoun DA. Resistant hypertension: an update of experimental and clinical findings. *Hypertension* 2017;70:5–9.
 6. Dahlöf B, Devereux RB, Kjeldsen SE, *et al.* Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359:995–1003.
 7. de la Sierra A, Segura J, Banegas JR, *et al.* Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. *Hypertension* 2011;57:898–902.
 8. Falaschetti E, Chaudhury M, Mindell J, *et al.* Continued improvement in hypertension management in England: results from the Health Survey for England 2006. *Hypertension* 2009;53:480–6.
 9. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. *J Hum Hypertens* 2014;28:463–8.
 10. Pepine CJ, Handberg EM, Cooper-DeHoff RM, *et al.* A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *JAMA* 2003;290:2805–16.
 11. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. *Hypertension* 2011;57:1076–80.
 12. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. *Am J Hypertens* 2015;28:355–61.
 13. Egan BM, Zhao Y, Li J, *et al.* Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. *Hypertension* 2013;62:691–7.
 14. McNaughton CD, Brown NJ, Rothman RL, *et al.* Systolic blood pressure and biochemical assessment of adherence: a cross-sectional analysis in the emergency department. *Hypertension* 2017;70:307–14.
 15. Jung O, Gechter JL, Wunder C, *et al.* Resistant hypertension? Assessment of adherence by toxicological urine analysis. *J Hypertens* 2013;31:766–74.
 16. Tomaszewski M, White C, Patel P, *et al.* High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. *Heart* 2014;100:855–61.
 17. Adeyemo A, Gerry N, Chen G, *et al.* A genome-wide association study of hypertension and blood pressure in African Americans. *PLoS Genet* 2009;5:e1000564.
 18. Kato N, Takeuchi F, Tabara Y, *et al.* Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. *Nat Genet* 2011;43:531–8.
 19. Levy D, Ehret GB, Rice K, *et al.* Genome-wide association study of blood pressure and hypertension. *Nat Genet* 2009;41:677–87.
 20. Newton-Cheh C, Johnson T, Gateva V, *et al.* Genome-wide association study identifies eight loci associated with blood pressure. *Nat Genet* 2009;41:666–76.
 21. Dumitrescu L, Ritchie MD, Denny JC, *et al.* Genome-wide study of resistant hypertension identified from electronic health records. *PLoS One* 2017;12:e0171745.
 22. Doris PA. The genetics of blood pressure and hypertension: the role of rare variation. *Cardiovasc Ther* 2011;29:37–45.
 23. Franceschini N, Le TH, Th L. Genetics of hypertension: discoveries from the bench to human populations. *Am J Physiol Renal Physiol* 2014;306:F1–F11.
 24. Ehret GB, Munroe PB, Rice KM, *et al.* Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* 2011;478:103–9.
 25. Hansson JH, Nelson-Williams C, Suzuki H, *et al.* Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. *Nat Genet* 1995;11:76–82.
 26. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. *Cell* 2001;104:545–56.
 27. Shimkets RA, Warnock DG, Bositis CM, *et al.* Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. *Cell* 1994;79:407–14.
 28. Luft FC. Mendelian forms of human hypertension and mechanisms of disease. *Clin Med Res* 2003;1:291–300.
 29. Ji W, Foo JN, O'Roak BJ, *et al.* Rare independent mutations in renal salt handling genes contribute to blood pressure variation. *Nat Genet* 2008;40:592–9.
 30. Gaziano JM, Concato J, Brophy M, *et al.* Million veteran program: a mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol* 2016;70:214–23.
 31. McCarty CA, Chisholm RL, Chute CG, *et al.* The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. *BMC Med Genomics* 2011;4:13.
 32. Roden DM, Pulley JM, Basford MA, *et al.* Development of a large-scale de-identified DNA biobank to enable personalized medicine. *Clin Pharmacol Ther* 2008;84:362–9.
 33. Newton KM, Peissig PL, Kho AN, *et al.* Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. *J Am Med Inform Assoc* 2013;20:e147–e154.
 34. Chow KM, Szeto CC, Wong TY, *et al.* Risk factors for thiazide-induced hyponatraemia. *QJM* 2003;96:911–7.
 35. Leung AA, Wright A, Pazo V, *et al.* Risk of thiazide-induced hyponatremia in patients with hypertension. *Am J Med* 2011;124:1064–72.
 36. Rodenburg EM, Hoorn EJ, Ruiter R, *et al.* Thiazide-associated hyponatremia: a population-based study. *Am J Kidney Dis* 2013;62:67–72.
 37. Weber MA, Schiffrin EL, White WB, *et al.* Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens* 2014;32:3–15.
 38. Xu H, Stenner SP, Doan S, *et al.* MedEx: a medication information extraction system for clinical narratives. *J Am Med Inform Assoc* 2010;17:19–24.
 39. Xu H, Doan S, Birdwell KA, *et al.* An automated approach to calculating the daily dose of tacrolimus in electronic health records. *AMIA Jt Summits Transl Sci Proc* 2010;2010:71–5.
 40. Xu H, Jiang M, Oetjens M, *et al.* Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. *J Am Med Inform Assoc* 2011;18:387–91.
 41. Levey AS, Bosch JP, Lewis JB, *et al.* A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;130:461–70.
 42. Tang H, Quertermous T, Rodriguez B, *et al.* Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. *Am J Hum Genet* 2005;76:268–75.
 43. Dumitrescu L, Ritchie MD, Brown-Gentry K, *et al.* Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. *Genet Med* 2010;12:648–50.
 44. Birdwell KA, Grady B, Choi L, *et al.* The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. *Pharmacogenet Genomics* 2012;22:32–42.
 45. Kirby JC, Speltz P, Rasmussen LV, Basford M, *et al.* PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. *J Am Med Inform Assoc* 2016;23:1046–52.
 46. Team RC. *R: a language and environment for statistical computing*. Vienna, Austria, 2017.
 47. Tocci G, Ferrucci A, Guida P, *et al.* Use of Electronic Support for Implementing Global Cardiovascular Risk Management. *High Blood Pressure & Cardiovascular Prevention* 2010;17:37–47.
 48. Abdel-Kader K, Dohar S, Shah N, *et al.* Resistant hypertension and obstructive sleep apnea in the setting of kidney disease. *J Hypertens* 2012;30:960–6.
 49. De Nicola L, Borrelli S, Gabbai FB, *et al.* Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease. *Kidney Blood Press Res* 2011;34:58–67.
 50. Egan BM, Zhao Y, Axon RN, *et al.* Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. *Circulation* 2011;124:1046–58.
 51. McAdam-Marx C, Ye X, Sung JC, *et al.* Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. *Clin Ther* 2009;31:1116–23.
 52. Logan AG, Perlikowski SM, Mente A, *et al.* High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. *J Hypertens* 2001;19:2271–7.

53. Martínez-García MA, Gómez-Aldaraví R, Gil-Martínez T, *et al.* [Sleep-disordered breathing in patients with difficult-to-control hypertension]. *Arch Bronconeumol* 2006;42:14–20.
54. Gonçalves SC, Martinez D, Gus M, *et al.* Obstructive sleep apnea and resistant hypertension: a case-control study. *Chest* 2007;132:1858–62.
55. Byrne C, Nedelman J, Luke RG. Race, socioeconomic status, and the development of end-stage renal disease. *Am J Kidney Dis* 1994;23:16–22.
56. Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. *Kidney Int* 2005;68:914–24.
57. Collins AJ, Foley RN, Chavers B, *et al.* 'United States renal data system 2011 annual data report: atlas of chronic kidney disease & end-stage renal disease in the United States. *Am J Kidney Dis* 2012;59(Suppl 1):e1–420.
58. Satko SG, Freedman BI, Moossavi S. Genetic factors in end-stage renal disease. *Kidney Int* 2005;67:S46–S49.
59. Graves JW, Bloomfield RL, Buckalew VM. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. *Am J Med Sci* 1989;298:361–5.
60. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. *Hypertension* 2002;39:982–8.
61. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. *J Am Coll Cardiol* 2008;52:1749–57.
62. Taylor AL, Ziesche S, Yancy C, *et al.* Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med* 2004;351:2049–57.
63. Dai WS, Kuller LH, Miller G. Arterial blood pressure and urinary electrolytes. *J Chronic Dis* 1984;37:75–84.
64. Frisancho AR, Leonard WR, Bollettino LA. Blood pressure in blacks and whites and its relationship to dietary sodium and potassium intake. *J Chronic Dis* 1984;37:515–9.
65. Mokwe E, Ohmit SE, Nasser SA, *et al.* Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. *Hypertension* 2004;43:1202–7.
66. Saunders E, Weir MR, Kong BW, *et al.* A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. *Arch Intern Med* 1990;150:1707–13.
67. Wright JT, Dunn JK, Cutler JA, *et al.* Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. *JAMA* 2005;293:1595–608.
68. Black HR, Weinberger MH, Purkayastha D, *et al.* Comparative efficacy and safety of combination amlodipine/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. *J Clin Hypertens* 2011;13:571–81.
69. Ferrario CM. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control. *Life Sci* 2010;86:289–99.
70. Djoumessi RN, Noubiap JJ, Kaze FF, *et al.* Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population. *BMC Res Notes* 2016;9:187.
71. Oxlund CS, Henriksen JE, Tarnow L, *et al.* Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. *J Hypertens* 2013;31:2094–102.
72. Oliveras A, Armario P, Clarà A, *et al.* Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. *J Hypertens* 2016;34:1863–71.
73. Williams B, MacDonald TM, Morant S, *et al.* Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet* 2015;386:2059–68.
74. NICE. Hypertension: the clinical management of primary hypertension in adults: update of Clinical Guidelines 18 and 34. Updated Nov 2016. <http://guidance.nice.org.uk/CB127> (accessed Mar 2018).
75. Mancia G, Fagard R, Narkiewicz K, *et al.* 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013;31:1281–357.
76. Burnier M, Schneider MP, Chioléro A, *et al.* Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. *J Hypertens* 2001;19:335–41.
77. Garg JP, Elliott WJ, Folker A, *et al.* Resistant hypertension revisited: a comparison of two university-based cohorts. *Am J Hypertens* 2005;18(5 Pt 1):619–26.
78. Schmieder RE, Ott C, Schmid A, *et al.* Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation. *J Am Heart Assoc* 2016;5.
79. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. *Circulation* 2012;125:1594–6.
80. Sim JJ, Bhandari SK, Shi J, *et al.* Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. *Mayo Clin Proc* 2013;88:1099–107.